News Detail
Maryland, 12 Sept 2024: Last week, Zydus Lifesciences confirmed the receipt of an FDA warning letter at its Waghodia plant in Gujarat, India, marking the latest in a string of production reprimands for the Indian drugmaker.
Now......
View Details
Source : Fierce Pharma
Zydus
U.S. FDA
FDA warning letter
injectable
drug manufacturing
Particle Contamination
facilities
India
FDA inspection
Facilities
Fierce Pharma Homepage
Manufacturing
Pharma
Related News
- STF of Bengal Police seized consignment of banned Phensedyl cough syrup worth Rs 1.5 crore (18-01-2025)
- DGFT issues new SOP for voluntary disclosure of SCOMET violations (18-01-2025)
- Private bodies providing essential services must fall under RTI Act: CIC (18-01-2025)
- 'In-Depth' Probe in Anaesthesia Drugs Complication Cases in Kashmir (18-01-2025)
- Guidelines to tackle Antimicrobial Resistance with Better Testing Machines (18-01-2025)
- IBM and L’Oreal to use gen AI model for sustainable cosmetic formulation (17-01-2025)
- Medical devices sector shows promising growth (17-01-2025)
- Nichlaul: Police arrested for running shop without license for 12 years (17-01-2025)
- Mamata suspends 12 doctors in expired saline case citing ‘medical negligence’ (17-01-2025)
- Halt illegal imports of refurbished medical devices: DCGI (17-01-2025)